These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 27927963)

  • 21. Extracellular prolyl oligopeptidase derived from activated microglia is a potential neuroprotection target.
    Natunen TA; Gynther M; Rostalski H; Jaako K; Jalkanen AJ
    Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):40-49. PubMed ID: 29998529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease.
    Torres ERS; Stanojlovic M; Zelikowsky M; Bonsberger J; Hean S; Mulligan C; Baldauf L; Fleming S; Masliah E; Chesselet MF; Fanselow MS; Richter F
    Neurobiol Dis; 2021 Oct; 158():105478. PubMed ID: 34390837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KYP-2047 penetrates mouse brain and effectively inhibits mouse prolyl oligopeptidase.
    Jalkanen AJ; Leikas JV; Forsberg MM
    Basic Clin Pharmacol Toxicol; 2014 Jun; 114(6):460-3. PubMed ID: 24350801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
    Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
    Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases.
    Hannula MJ; Myöhänen TT; Tenorio-Laranga J; Männistö PT; Garcia-Horsman JA
    Neuroscience; 2013 Jul; 242():140-50. PubMed ID: 23562579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing α-Synuclein.
    Schidlitzki A; Stanojlovic M; Fournier C; Käufer C; Feja M; Gericke B; Garzotti M; Welford RWD; Steiner MA; Angot E; Richter F
    Mov Disord; 2023 Jun; 38(6):1044-1055. PubMed ID: 37050861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.
    Savolainen MH; Albert K; Airavaara M; Myöhänen TT
    Exp Brain Res; 2017 Jul; 235(7):2189-2202. PubMed ID: 28439627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolyl oligopeptidase inhibition reduces oxidative stress via reducing NADPH oxidase activity by activating protein phosphatase 2A.
    Eteläinen T; Kulmala V; Svarcbahs R; Jäntti M; Myöhänen TT
    Free Radic Biol Med; 2021 Jun; 169():14-23. PubMed ID: 33838285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.
    Fleming SM; Mulligan CK; Richter F; Mortazavi F; Lemesre V; Frias C; Zhu C; Stewart A; Gozes I; Morimoto B; Chesselet MF
    Mol Cell Neurosci; 2011 Mar; 46(3):597-606. PubMed ID: 21193046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein.
    Richter F; Subramaniam SR; Magen I; Lee P; Hayes J; Attar A; Zhu C; Franich NR; Bove N; De La Rosa K; Kwong J; Klärner FG; Schrader T; Chesselet MF; Bitan G
    Neurotherapeutics; 2017 Oct; 14(4):1107-1119. PubMed ID: 28585223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Carnosine Intervention in the Thy1-aSyn Mouse Model of Parkinson's Disease.
    Bermúdez ML; Seroogy KB; Genter MB
    Neuroscience; 2019 Jul; 411():270-278. PubMed ID: 31125602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intranasal Carnosine Mitigates α-Synuclein Pathology and Motor Dysfunction in the Thy1-aSyn Mouse Model of Parkinson's Disease.
    Brown JM; Baker LS; Seroogy KB; Genter MB
    ACS Chem Neurosci; 2021 Jul; 12(13):2347-2359. PubMed ID: 34138535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.
    Henrich MT; Geibl FF; Lee B; Chiu WH; Koprich JB; Brotchie JM; Timmermann L; Decher N; Matschke LA; Oertel WH
    Acta Neuropathol Commun; 2018 May; 6(1):39. PubMed ID: 29747690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Behavioural and dopaminergic changes in double mutated human A30P*A53T alpha-synuclein transgenic mouse model of Parkinson´s disease.
    Kilpeläinen T; Julku UH; Svarcbahs R; Myöhänen TT
    Sci Rep; 2019 Nov; 9(1):17382. PubMed ID: 31758049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The proSAAS Chaperone Provides Neuroprotection and Attenuates Transsynaptic α-Synuclein Spread in Rodent Models of Parkinson's Disease.
    Lindberg I; Shu Z; Lam H; Helwig M; Yucer N; Laperle A; Svendsen CN; Di Monte DA; Maidment NT
    J Parkinsons Dis; 2022; 12(5):1463-1478. PubMed ID: 35527562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson's disease: historical overview and future prospects.
    Nagatsu T
    J Neural Transm (Vienna); 2017 Jun; 124(6):739-744. PubMed ID: 27503084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alpha-Synuclein Expression Restricts RNA Viral Infections in the Brain.
    Beatman EL; Massey A; Shives KD; Burrack KS; Chamanian M; Morrison TE; Beckham JD
    J Virol; 2015 Dec; 90(6):2767-82. PubMed ID: 26719256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prolyl oligopeptidase inhibitor reduces tau pathology in cellular models and in mice with tauopathy.
    Eteläinen TS; Silva MC; Uhari-Väänänen JK; De Lorenzo F; Jäntti MH; Cui H; Chavero-Pieres M; Kilpeläinen T; Mechtler C; Svarcbahs R; Seppälä E; Savinainen JR; Puris E; Fricker G; Gynther M; Julku UH; Huttunen HJ; Haggarty SJ; Myöhänen TT
    Sci Transl Med; 2023 Apr; 15(691):eabq2915. PubMed ID: 37043557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
    Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
    Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.